Back

Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro biofilm and in vivo implant infections

de Vor, L.; van Dijk, B.; van Kessel, K. P.; Kavanaugh, J. S.; de Haas, C. J.; Aerts, P. C.; Viveen, M. C.; Boel, E. C.; Fluit, A. C.; Kwiecinski, J. M.; Krijger, G. C.; Ramakers, R. M.; Beekman, F. J.; Dadachova, E.; Lam, M. G.; Vogely, H. C.; van der Wal, B. C.; van Strijp, J. A.; Horswill, A. R.; Weinans, H.; Rooijakkers, S. H.

2021-02-09 microbiology
10.1101/2021.02.09.429966 bioRxiv
Show abstract

Implant-associated Staphylococcus aureus infections are difficult to treat because of biofilm formation. Bacteria in a biofilm are often insensitive to antibiotics and host immunity. Monoclonal antibodies (mAbs) could provide an alternative approach to improve the diagnosis and/or treatment of biofilm-related infections. Here we show that mAbs targeting common surface components of S. aureus can recognize clinically relevant biofilm types. We identify two groups of antibodies: one group that uniquely binds S. aureus in biofilm state and one that recognizes S. aureus in both biofilm and planktonic state. In a mouse model, we show that mAb 4497 (recognizing wall teichoic acid (WTA)) specifically localizes to biofilm-infected implants. In conclusion, we demonstrate the capacity of several human mAbs to detect S. aureus biofilms in vitro and in vivo. This is an important first step to develop mAbs for imaging or treating S. aureus biofilms.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.